BMG Pharma S.r.l

BMG Pharma S.r.l is an Italian pharmaceutical company and the world's first pharmaceutical company to develop products based on modified sodium hyaluronate. The headquarters of BMG is currently located in Milan, Italy. It is a business-to-business company, and its business model is based on signing distribution and licensing agreements for the sale and distribution of its products with companies around the world. In 2018, BMG acquired another Italian company, Sigea S.r.l, which has expertise in developing targeted functional ingredients, with a particular focus on modified sodium hyaluronate.